Compare XAIR & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XAIR | PTHL |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.8M |
| IPO Year | N/A | 2024 |
| Metric | XAIR | PTHL |
|---|---|---|
| Price | $1.35 | $0.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 112.9K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,802,000.00 | $448,196.00 |
| Revenue This Year | $261.11 | N/A |
| Revenue Next Year | $151.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $1.19 | $0.47 |
| 52 Week High | $11.56 | $32.00 |
| Indicator | XAIR | PTHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 44.14 |
| Support Level | $1.19 | $0.55 |
| Resistance Level | $1.38 | $0.62 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 20.15 | 58.80 |
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.